8-K: Marpai Secures Key Financial Agreements, Amends AXA Deal and Obtains $1.7 Million Funding

Marpai, Inc. has amended its agreement with AXA, extending payment terms and potentially reducing obligations, while also securing $1.7 million in revenue-based financing from Libertas Funding, LLC.

Summary

• Marpai, Inc. has entered into an amendment with AXA S.A. regarding the Maestro Health acquisition, which extends payment terms and could reduce the overall payment obligation by $3 million if certain criteria are met.
• The amendment reduces the 2024 payment to $473,688 and delays further payments to 2025.
• The reduction criteria include Marpai's largest shareholder contributing at least $3 million in equity, maintaining a Nasdaq listing, and making timely payments under the AXA agreement between February 29, 2024, and April 15, 2024.
• Marpai also secured $1.7 million in revenue-based financing from Libertas Funding, LLC, to be used for short-term working capital needs.
• The Libertas agreement involves selling future receipts totaling $2,193,000 for a purchase price of $1,700,000, with weekly deliveries over nine months.
• The company's CEO, Damien Lamendola, has provided a guarantee for the Libertas funding agreement.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the improved payment terms with AXA and the new financing from Libertas. However, there are still risks and obligations that need to be managed, which prevents a higher score.

Positives

• The amendment with AXA provides significant relief on payment terms and reduces the immediate financial burden on Marpai.
• The potential $3 million reduction in the AXA payment obligation is a substantial benefit if the criteria are met.
• The $1.7 million in revenue-based financing from Libertas provides flexible capital without diluting shareholders.
• The CEO's commitment to invest $3 million demonstrates confidence in the company's future.

Negatives

• The Libertas funding involves selling future receipts at a discount, which could impact future cash flow.
• The company is still obligated to make substantial payments to AXA in the coming years, even with the amended terms.
• The reduction in the AXA payment is contingent on meeting specific criteria, which introduces uncertainty.

Risks

• Marpai must meet the Reduction Criteria by December 31, 2024, to achieve the $3 million reduction in the AXA payment.
• Failure to make timely payments under the AXA agreement could result in increased payment obligations.
• The company's reliance on revenue-based financing could create pressure on future cash flow if revenue does not meet expectations.
• The guarantee provided by the CEO for the Libertas funding agreement could expose him to personal financial risk.

Future Outlook

Marpai aims to use the new financing to support its growth initiatives and working capital needs, while the amended AXA agreement provides a more manageable payment schedule. The company is focused on executing its operating plan and achieving its growth objectives.

Management Comments

• Damien Lamendola, CEO, stated that the AXA amendment removes a significant overhang for the business and allows the company to push forward aggressively on growth actions.
• Steve Johnson, CFO, mentioned that the Libertas financing provides flexible capital without diluting shareholders.

Industry Context

Marpai operates in the Third-Party Administration (TPA) sector, which is a $22 billion market. The company's focus on self-funded employer health plans aligns with a growing trend in the healthcare industry where employers are seeking more control over their healthcare costs. The financing agreements will help Marpai compete more effectively in this market.

Comparison to Industry Standards

• The revenue-based financing from Libertas is a common method for small to medium-sized businesses to access capital, but the terms, including the discount on future receipts, are specific to Marpai's situation.
• The amendment to the AXA agreement is a unique situation arising from the acquisition of Maestro Health and the subsequent payment obligations. It is not directly comparable to standard industry practices.
• The commitment from the CEO to invest $3 million in equity is a strong signal of confidence, which is not always seen in similar situations.

Related Party Transactions

• The CEO, Damien Lamendola, provided a guarantee for the Libertas funding agreement through various entities he controls.

Stakeholder Impact

• Shareholders may view the amended AXA agreement and the new financing as positive developments, potentially increasing confidence in the company.
• Employees may benefit from the company's improved financial stability and growth prospects.
• Customers may see the company as a more reliable partner due to its improved financial position.
• Creditors may be more confident in the company's ability to meet its obligations.

Next Steps

• Marpai needs to ensure it meets the Reduction Criteria by December 31, 2024, to achieve the $3 million reduction in the AXA payment.
• The company must make timely payments to AXA as per the amended agreement.
• Marpai will need to manage its cash flow to meet the weekly delivery obligations to Libertas.
• The company will need to execute its operating plan to utilize the new capital effectively.

Key Dates

Keywords

Marpai, AXA, Libertas Funding, financing, revenue-based financing, payment terms, Maestro Health, capital raise, debt reduction, working capital